lisocabtagene maraleucel,ibrutinib,venetoclax
Bms,Roche,Abbvie,janssen
['lymsm', 'cll 004', 'liso-cel', 'transcend cll 004', 'transcend,(-nhl-001),(-nhl 001),(-nhl001),(-nhl-006),(-nhl 006),(-nhl006),(-pilot-017006),(-pilot017006),(-pilot 017006)', 'lymphoma', 'cll']
congress|#17icml tanya siddiqi of reports on the primary analysis of transcend cll 004 evaluating liso-cel in untreated, high-risk patients with r/r cll/sll. liso-cel led to deep and durable responses, high umrd rates, and a manageable safety profile
#lymsm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm